Clinical Trial Update: IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial (IMM 0212) evaluated a busulfan with fludarabine and antithymocyte globulin preparative regimen before hematopoietic stem cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)
• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)

Snippet

Sponsor: Emory University | Conditions: T-Cell Immune Deficiency Diseases, Severe Combined Immunodeficiency | Phase 1, Phase 2 | Status: COMPLETED